Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children

• Published in: Pediatric nephrology (Berlin, West) Vol. 37; no. 3; pp. 499 - 508
• Main Authors: Vaz de Castro, Pedro Alves Soares, Bitencourt, Letícia, Pereira, Bruno Wilnes Simas, Lima, Ananda Queiroz Rocha, Hermida, Henrique Santos, Moreira Neto, Carlos Roberto, Mestriner, Mariana Dinamarco, Simões e Silva, Ana Cristina
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2022; Springer; Springer Nature B.V
• Subjects: ACE inhibitors; Adult; Angiotensin; Angiotensin II; Angiotensin Receptor Antagonists - adverse effects; Angiotensin-converting enzyme inhibitors; Angiotensin-Converting Enzyme Inhibitors - adverse effects; Care and treatment; Child; Children; Clinical trials; Cross-Sectional Studies; Diagnosis; Diseases; Diuretics; Dosage and administration; Enzymes; Female; Glomerulonephritis, IGA - drug therapy; Hematuria; Humans; IgA glomerulonephritis; IgA nephropathy; Immunoglobulin A; Kidney diseases; Literature reviews; Male; Medicine; Medicine & Public Health; Nephrology; Nitric-oxide synthase; Oxidative stress; Patients; Pediatrics; Peptidyl-dipeptidase A; Placebos; Proteinuria; Proteinuria - drug therapy; Quality control; Safety; Systematic review; Systematic Review/Meta-analysis; Testing; Urology; Young Adult; Brazil; Angiotensin-converting enzyme inhibitors; Chronic kidney disease; IgA nephropathy; Children; Angiotensin receptor blockers; Proteinuria

Background IgA nephropathy (IgAN) is one of the most prevalent primary glomerulopathies in children. There are various studies investigating the efficacy of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in adults with IgAN. However, only few studies evalu...